Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions.
(2009) In Scandinavian Journal of Gastroenterology 44. p.782-786- Abstract
- Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1... (More)
- Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1302576
- author
- Andersson, Roland LU ; Aho, Ursula LU ; Nilsson, Bo ; Peters, Godefridus ; Pastor-Anglada, Marcal ; Rasch, Wenche and Sandvold, Marit
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Gastroenterology
- volume
- 44
- pages
- 782 - 786
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000268579400003
- pmid:19214867
- scopus:70350635407
- pmid:19214867
- ISSN
- 1502-7708
- DOI
- 10.1080/00365520902745039
- language
- English
- LU publication?
- yes
- id
- 0340dab7-0cd1-48b5-b48d-4b1196e0f759 (old id 1302576)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19214867?dopt=Abstract
- date added to LUP
- 2016-04-04 09:40:36
- date last changed
- 2022-01-29 18:59:40
@article{0340dab7-0cd1-48b5-b48d-4b1196e0f759, abstract = {{Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.}}, author = {{Andersson, Roland and Aho, Ursula and Nilsson, Bo and Peters, Godefridus and Pastor-Anglada, Marcal and Rasch, Wenche and Sandvold, Marit}}, issn = {{1502-7708}}, language = {{eng}}, pages = {{782--786}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Gastroenterology}}, title = {{Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions.}}, url = {{http://dx.doi.org/10.1080/00365520902745039}}, doi = {{10.1080/00365520902745039}}, volume = {{44}}, year = {{2009}}, }